We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rheumatoid Arthritis Diagnosed by Anti-CCP Assay

By LabMedica International staff writers
Posted on 07 Sep 2009
Print article
A highly specific assay for the diagnosis of rheumatoid arthritis (RA) also predicts the eventual development of RA when found in undifferentiated arthritis. The fully automated, second generation test determines human immunoglobulin G (IgG) autoantibodies to cyclic citrullinated peptides (anti-CCP) in serum or plasma.

The anti-CCP assay is more precise than tests for other RA markers such as rheumatoid factor (RF) and C-reactive protein (CRP). The assay uses a small sample volume (15µL) and produces reliable results in just 18 minutes. The February 2009 National Institute for Health and Clinical Excellence (NICE; London, UK) guideline recommends testing for anti-CCP, in the management of patients with suspected RA where tests for RF are negative.

RA is diagnosed according to clinical manifestations and laboratory investigations. Common laboratory tests for RA include assays for RF, C-reactive protein (CRP) and antibodies to cyclic citrullinated protein (anti-CCP). RF is nonspecific for RA, because it may be present in healthy elderly persons or patients with other autoimmune or infectious diseases; CRP is a general inflammation marker whereas anti-CCP is highly specific for RA.

Rheumatoid arthritis is a chronic, inflammatory autoimmune disorder that affects approximately 1% of the population in the UK and Ireland. The condition is often severely disabling, causing a loss of mobility due to pain and joint destruction.

The new test for RA is called the Elecsys Anti-CCP assay and is available on the Roche Diagnostics (Burgess Hill, UK) modular analytics, cobas 6000 and cobas 4000 systems. Clinical laboratories can consolidate testing for a number of different autoimmune tests including RF and CRP on a single serum work area (SWA) platform.

With 183 different assays, Roche offers a large menu of tests (including its immunology test portfolios) for an automated SWA, allowing laboratories to perform the assays in-house on a single platform.

Related Links:
Roche Diagnostics

Gold Member
Hematology Analyzer
Swelab Lumi
Automated Blood Typing System
IH-500 NEXT
New
Free Human Prostate-Specific Antigen CLIA
LIAISON fPSA
New
Urine Strips
11 Parameter Urine Strips

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.